Semaglutide vs Tirzepatide

In SURPASS-2, a randomized head-to-head trial of adults with type 2 diabetes taking metformin, tirzepatide produced greater weight reduction than semaglutide.¹ Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, while semaglutide activates GLP-1 receptors alone. Your physician should choose between them based on your medical history, tolerability, goals, and the boxed warning shared by both labels.^2,3 At Opt Health, a physician reads every lab we order before treatment is offered.

Mechanism in the Semaglutide vs Tirzepatide Comparison

Semaglutide and tirzepatide affect appetite through related pathways, but the drugs do not have the same receptor targets. That difference helps explain why a physician may consider both options instead of treating them as interchangeable.

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. It selectively activates the GLP-1 receptor, which is present in areas of the brain involved in appetite regulation. The Wegovy label describes GLP-1 as a physiological regulator of appetite and caloric intake.³

Tirzepatide activates both GIP and GLP-1 receptors. The Zepbound label states that receptors for both hormones are present in brain regions involved in appetite regulation. Nonclinical studies suggest that the added GIP activity may further affect food intake, but those findings came from animal research.²

The dual-receptor mechanism gives tirzepatide a biological difference from semaglutide. The mechanism alone cannot tell you how much weight you would lose, which adverse reactions you would experience, or whether tirzepatide is a better fit for your medical history. Those questions require clinical evidence and physician review.

Brand names can make this comparison confusing. Wegovy is a weight-management brand of semaglutide, and Ozempic is also a semaglutide brand. Zepbound is the tirzepatide brand covered by the weight-management label used in this comparison.^2,3 A search for semaglutide vs tirzepatide vs Ozempic therefore includes the same active drug twice.

Drug	Receptor Target	Brand Names Men Will Recognize	What the Head-to-Head Trial Found	Boxed Warning
Semaglutide	Selective GLP-1 receptor agonist	Wegovy and Ozempic	In adults with type 2 diabetes taking metformin, semaglutide was the active comparator in SURPASS-2. Tirzepatide produced larger reductions in glycated hemoglobin and body weight during the 40-week trial.1	Thyroid C-cell tumors. The label contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2.3
Tirzepatide	Dual GIP and GLP-1 receptor agonist	Zepbound	In adults with type 2 diabetes taking metformin, all three tirzepatide trial arms were noninferior and superior to semaglutide for the change in glycated hemoglobin. Estimated body-weight differences also favored tirzepatide.1	Thyroid C-cell tumors. The label contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2.2

The table separates mechanism from outcome evidence. The labels establish how each drug works and describe each product’s warnings. They do not provide a controlled comparison because the drugs were evaluated in separate development programs with different study designs and populations.

SURPASS-2 supplies the direct randomized comparison. Its results favor tirzepatide for specific outcomes in a defined population, but the trial did not enroll men seeking weight management without diabetes. That boundary affects how your physician should interpret the numbers.

The Head-to-Head Evidence from SURPASS-2

SURPASS-2 compared tirzepatide directly with semaglutide in patients with type 2 diabetes who were taking metformin.¹ The trial provides more useful comparative evidence than placing results from separate single-drug studies side by side. Its population and treatment arms still limit how far the findings can be applied.

The SURPASS-2 Trial Design

SURPASS-2 was an open-label, phase 3 trial that ran for 40 weeks. Investigators randomized 1,879 patients in a 1:1:1:1 ratio to three tirzepatide arms or one semaglutide arm. The tirzepatide trial doses were 5 mg, 10 mg, and 15 mg, while the semaglutide trial dose was 1 mg.¹

Those amounts describe what the researchers studied. They are not prescribing recommendations. Your prescription may involve a different product, clinical goal, or treatment decision.

At baseline, participants had a mean glycated hemoglobin level, or HbA1c, of 8.28%. The mean age was 56.6 years, and the mean body weight was 93.7 kg.¹ These details place the results in adults whose primary study context was type 2 diabetes treated with metformin.

The trial’s primary endpoint was the change in HbA1c from baseline through week 40. Body-weight change and adverse events added information that is relevant to a weight-management discussion, but the study was designed around diabetes treatment.

The Glycemic Results

Tirzepatide produced larger mean HbA1c reductions than semaglutide in the SURPASS-2 population. The estimated mean changes were minus 2.01, minus 2.24, and minus 2.30 percentage points across the three tirzepatide arms. The semaglutide group had an estimated mean change of minus 1.86 percentage points.¹

The estimated treatment differences versus semaglutide were minus 0.15 percentage points for the 5 mg tirzepatide arm, minus 0.39 percentage points for the 10 mg arm, and minus 0.45 percentage points for the 15 mg arm. The published confidence intervals excluded zero, and the differences were statistically significant. Investigators reported that every tirzepatide arm was noninferior and superior to semaglutide for the HbA1c endpoint.¹

These findings apply to adults with type 2 diabetes taking metformin. If your primary goal is weight management and you do not have diabetes, the HbA1c findings do not answer your main treatment question. They describe blood-sugar outcomes in the population that SURPASS-2 enrolled.

The Body-Weight Results

Body-weight reduction also favored tirzepatide in the adults with type 2 diabetes taking metformin. Compared with semaglutide, the estimated treatment differences were minus 1.9 kg, minus 3.6 kg, and minus 5.5 kg across the three tirzepatide arms. Each comparison had a reported P value below 0.001.¹

These numbers are differences between the treatment groups. The abstract does not provide the absolute mean weight change for each group in the quoted results, so the kilogram differences should not be presented as the amount you can expect to lose.

The pattern was dose-related within the tirzepatide arms studied. That does not give you a reason to choose a trial dose for yourself. Your prescriber sets treatment according to the approved product label, your medical history, your response, and your tolerability.

SURPASS-2 supports a narrow conclusion. Tirzepatide produced greater weight reduction than semaglutide over 40 weeks in adults with type 2 diabetes taking metformin.¹ It did not establish that every man using tirzepatide for weight management will lose more weight than he would with semaglutide.

The Adverse Events in SURPASS-2

Gastrointestinal events were the most common adverse events in the SURPASS-2 population. Investigators described them as primarily mild to moderate in severity across the tirzepatide and semaglutide groups.¹

Nausea occurred in 17% to 22% of patients receiving tirzepatide and 18% of patients receiving semaglutide. Diarrhea occurred in 13% to 16% of the tirzepatide groups and 12% of the semaglutide group. Vomiting occurred in 6% to 10% of patients receiving tirzepatide and 8% of patients receiving semaglutide.¹

Serious adverse events were reported in 5% to 7% of patients receiving tirzepatide and 3% of patients receiving semaglutide.¹ Those percentages do not show that a particular event was caused by the drug. They report how many trial participants experienced an event classified as serious.

SURPASS-2 was funded by Eli Lilly, the manufacturer of tirzepatide.^1,2 The trial favored tirzepatide, which was Lilly’s own drug. Industry funding does not decide whether the reported results are correct, but the funding relationship belongs alongside the efficacy and safety findings.

The Limits of Extrapolating SURPASS-2

The SURPASS-2 percentages and kilogram differences should not be applied directly to someone without diabetes who is not taking metformin. The metabolic context differs, and the trial’s primary endpoint focused on HbA1c. A man pursuing weight management may also have different baseline weight, medical conditions, medications, and treatment goals.

The drug amounts tested also bound the comparison. SURPASS-2 compared three specific tirzepatide trial arms with one specific semaglutide trial arm. It did not evaluate every formulation or prescribing plan that a physician might consider.

The 40-week window adds another boundary. It shows what happened during the study period, but it does not answer how the two drugs compare over several years. It also does not establish what happens after treatment changes or ends.

A direct weight-management trial in adults without diabetes would change the strength of the comparison. Sex-stratified results and head-to-head body-composition measurements would also help answer questions that SURPASS-2 leaves open. Until those data are available, your physician has to separate what the study measured from what you want treatment to accomplish.

Side-Effect Comparison

The semaglutide vs tirzepatide side-effect comparison centers largely on gastrointestinal tolerability. Both the weight-management labels describe gastrointestinal adverse reactions, and SURPASS-2 reported nausea, diarrhea, and vomiting in both treatment groups.^1-3 Your experience cannot be predicted from the group percentages alone.

The Zepbound label names several gastrointestinal categories rather than grouping every symptom under one broad phrase. These include diarrhea and frequent bowel movements, constipation and reports coded as feces hard, and abdominal symptoms. The abdominal category covers discomfort, upper or lower abdominal pain, and tenderness.² These categories give your prescriber a more precise way to discuss what you experienced and whether the pattern affected treatment.

The wording matters during a consultation. Frequent bowel movements can affect your day differently from abdominal tenderness, even though both fall within a gastrointestinal safety discussion. Describe the specific symptom, when it began, and how it affected eating or daily activity instead of reporting only that your stomach felt off.

The Wegovy label provides semaglutide’s product-specific safety information, while the Zepbound label provides tirzepatide’s safety information.^2,3 Rates from separate label trials should not be treated as if the drugs were tested against each other under identical conditions. SURPASS-2 is the cleaner source when you want a direct comparison, though its diabetes-on-metformin population remains a limitation.

The Zepbound weight-reduction trials also report permanent discontinuation because of adverse reactions. Discontinuation occurred in 4.8%, 6.3%, and 6.7% of patients across the three Zepbound trial arms, compared with 3.4% of patients receiving placebo.² Most discontinuations attributed to Zepbound adverse reactions occurred during the first few months and were associated with gastrointestinal reactions.

Those discontinuation rates come from Zepbound’s own placebo-controlled trials. They do not establish a Zepbound-versus-Wegovy discontinuation advantage or disadvantage. They show that gastrointestinal tolerability can become important enough for some participants to stop treatment.

Your history gives those figures context. A prescriber may ask about prior nausea, vomiting, diarrhea, constipation, abdominal pain, and the effect those symptoms had on eating or hydration. That information can influence initial drug selection and later treatment decisions without turning a trial average into a prediction for you.

Side effects also need to be interpreted alongside results. A larger average weight change has limited value if adverse reactions make treatment difficult to continue. A smaller average difference may be acceptable when a drug fits your medical history and is better tolerated.

The Shared Boxed Warning and Contraindications

Both labels carry a boxed warning concerning thyroid C-cell tumors. The labels contraindicate these drugs in anyone with a personal or family history of medullary thyroid carcinoma (MTC). They also contraindicate use in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).^2,3

MTC is a form of thyroid cancer named directly in the prescribing labels. MEN 2 is an inherited syndrome associated with endocrine tumors. If either condition appears in your personal or family history, your prescriber needs that information before considering either drug.

This warning applies to both sides of the comparison. Switching from semaglutide to tirzepatide does not remove the shared contraindication. The receptor difference does not change what the labels state about MTC or MEN 2.

A family-history discussion should identify the diagnosis when possible. A general report of thyroid disease does not tell your physician whether the condition was MTC, another form of thyroid cancer, or a noncancerous thyroid disorder. Your physician can decide what records or clarification are needed before treatment is considered.

Trial Population Fit for Men

The available trial populations do not support a claim that either drug works better for men specifically. SURPASS-2 reported combined results from adults with type 2 diabetes, without a male-only efficacy comparison in the published abstract.¹ Drug choice for you should not be based on a sex-specific advantage that these sources did not measure.

The Zepbound label reports that 37% of participants across its weight-reduction trials were male.² That figure belongs only to the Zepbound trial population described in the label. It is not a semaglutide statistic, and it does not show that men respond differently from women.

For a men’s-health decision, the 37% figure is a scope check. Men were represented, but they were a minority of that trial population. The label does not provide evidence in the quoted material that allows your physician to predict a different weight response based on sex.

Your goals may also extend beyond the number on a scale. You may care about waist size, strength, gym performance, energy, glucose control, and maintaining lean mass. The cited head-to-head evidence does not measure every one of those outcomes.

SURPASS-2 reported total body-weight differences. It did not provide a head-to-head breakdown of fat mass and lean mass between semaglutide and tirzepatide in the published abstract.¹ A larger reduction in body weight therefore cannot be assumed to mean a better body-composition result for you.

A physician can follow your weight response alongside symptoms, medical conditions, current medications, and relevant laboratory patterns. One number gives one part of the response. A treatment decision becomes clearer when the physician can see how several related measures change together.

Factors in a Physician’s Choice

A physician may choose semaglutide or tirzepatide for reasons that extend beyond average weight loss. The receptor mechanism, medical history, contraindications, prior gastrointestinal symptoms, and response during follow-up all affect the decision.

Semaglutide selectively activates GLP-1 receptors, while tirzepatide activates GIP and GLP-1 receptors.^2,3 A prescriber may consider that difference alongside the direct evidence from SURPASS-2. The dual mechanism does not make tirzepatide an automatic choice.

The SURPASS-2 weight findings may carry more relevance if you also have type 2 diabetes and take metformin because that situation more closely matches the trial population. Even then, your baseline HbA1c, body weight, other medications, and tolerability may differ from the trial averages.

If you do not have diabetes, the trial provides comparative information with a larger gap between the study population and your own situation. Your physician can acknowledge the direction of the finding while avoiding a promise based on the reported kilogram differences.

Gastrointestinal history can change the discussion. Prior problems with nausea, diarrhea, vomiting, constipation, frequent bowel movements, or abdominal discomfort may influence how your prescriber weighs the label information. Follow-up matters because tolerability can become clearer only after treatment begins under clinical direction.

The shared boxed warning can remove both drugs from consideration when MTC or MEN 2 is present in your personal or family history.^2,3 This is a label-based contraindication rather than a preference between two otherwise suitable options.

Cost can differ between products and prescribing arrangements, but these sources do not provide comparable price data. For a general explanation of why treatment totals vary, see how prescription and monitoring costs are built. Your comparison should use the full expected cost attached to the specific prescription rather than a promotional monthly figure.

If you need more information about semaglutide on its own, the semaglutide weight-loss overview covers that separate question. The decision between semaglutide and tirzepatide requires a narrower comparison of mechanism, direct evidence, warnings, and tolerability.

A head-to-head weight-management trial in adults without diabetes could change the confidence placed in the SURPASS-2 weight findings. A trial reporting male results separately and measuring fat mass against lean mass would further change the answer. Those data would connect the evidence more closely to the goals many men bring to treatment.

The Opt Take on Medication Selection

Choosing between these medications starts after testing, when a physician interprets your labs alongside your health history, symptoms, goals, current medications, and daily life. Trial averages can frame the decision, but they cannot select the right treatment for you. Your physician looks for patterns across your data and considers how each option fits your risk profile and ability to tolerate treatment.

At Opt Health, the choice is part of an individualized plan rather than a standard prescription pathway. Your response, side effects, and updated biomarkers guide what happens next. The process continues through testing, understanding, treatment, retesting, and adjustment.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.